計劃和組織《今日藥物》是一份同行評議的期刊，在科學出版物市場上享有40多年的聲譽。它是關于藥物進入國際市場的寶貴資料來源。其最新的專著和文章，使醫學界的最新發展，在診斷和治療跨治療領域。本期刊包括以下部分:通過對文獻和制藥公司提供的信息的嚴格審查，由領先專家編寫的關于最近批準和推出的藥物的專著和最新評論。此外，亦會公布最新的有關資料或已上市藥物的最新資料(例如新配方、新適應癥等)。綜述文章，重點介紹人類疾病診斷和治療的最新進展，以及用于診斷疾病、監測治療反應、預測毒性和確定靶向治療候選藥物的生物標志物。會議報告，會議報告提供的重點從世界各地的主要大會和研討會。選擇要審查的主題編輯委員會由各自領域的主要權威人士組成，他們被挑選出來，以確保涵蓋廣泛的治療領域。執行局成員建議由其領域內的當局進行審查，以確保全面涵蓋所有主題，并強調所有當前重要的問題。提交的文章在發表前要經過同行評審。定期出版關于最近銷售的藥品和專題討論會論文集的補充問題。補編是由領先的專家根據當前的科學文獻和他們自己的經驗編寫的。p-ISSN: 1699-3993, e-ISSN: 1699-4019 (B-47252-2009)成立:1965出版:12期/年和補編讀者簡介:醫學專家，臨床醫生，市場營銷和企業戰略總監，藥劑師和藥理學家

AIMS & ORGANIZATIONDrugs of Today is a peer-reviewed journal with a solid reputation of over 40 years in the scientific publications market. It is a valuable source of information on drugs introduced into the international market. Its updated monographs and articles keep the medical community abreast of the latest developments in diagnosis and treatment across therapeutic areas. This journal includes the following sections:Monographs, up-to-date reviews on recently approved and launched drugs prepared by leading specialists after a rigorous review of the literature and from information provided by pharmaceutical companies. Updates with new relevant information or on line extensions of marketed drugs (e.g., novel formulations, new indications, etc.) are also published.Review articles, highlighting the latest developments in the diagnosis and treatment of human diseases, as well as biomarkers for diagnosing diseases, monitoring treatment response, predicting toxicity and identifying candidates for targeted therapy.Meeting reports, conference reports providing highlights from key congresses and symposia around the world.SELECTION OF TOPICS TO BE REVIEWEDThe Editorial Board comprises major authorities in their field who are selected to ensure that a wide variety of therapeutic areas are covered. The Board members recommend reviews from authorities within their field to guarantee that all topics are covered comprehensively and that all issues of current importance are emphasized. Submitted articles are peer reviewed before publication.Supplementary issues devoted to recently marketed drugs and symposia proceedings are periodically published. Supplements are written by leading specialists on the basis of current scientific literature and their own experience. p-ISSN: 1699-3993, e-ISSN: 1699-4019 (B-47252-2009) Established: 1965 Published: 12 issues/year and supplements Reader profile: Medical specialists, clinicians, marketing & corporate strategy directors, pharmacists & pharmacologists